Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer

D. H. Johnson, J. D. Hainsworth, R. De Vore, K. R. Hande, F. A. Greco

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Forty-two patients with unresectable non-small cell lung cancer (NSCLC) were treated with carboplatin (300. 350 or 400 mg/m2) and 21 days of oral etoposide (50 mg/m2 day). Thirty-three patients were evaluable for response (too early to assess the remaining patients) and 9 patients (27%) achieved a partial remission. Median survival was 29 weeks (range, 4+ to 71 + weeks). The primary toxicity was myelosuppression. Leukocyte and platelet count nadirs occurred between days 22 and 29. In cycle 1. median leukocyte nadir was 2.8 x 109 1 and the platelet nadir was 142 x 109/1. Nonhematologic toxicides were modest and included alopecia in all patients, mild nausea, mild to moderate diarrhea, and an occasional increase in serum creatinine. Carboplatin plus oral etoposide is a tolerable outpatient regimen with modest activity against unresectable NSCLC.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalOncology (Switzerland)
Volume49
DOIs
StatePublished - Jan 1 1992

Keywords

  • Carboplatin
  • Etoposide
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this